Lindsay Dougherty
Adult Health · Philadelphia, PANPI 1669957155
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,028 of the $12,248 with a category attached, or 98.2%. 7 manufacturers reported payments, led by Johnson & Johnson at 41.3% of the total. 2025 is the largest year on record at $7,137, more than ten times the $32 reported in 2022. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $720.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- Janssen Scientific Affairs, LLC$5K
- Janssen Global Services, LLC$2K
- Daiichi Sankyo Inc.$75
- Regeneron Healthcare Solutions, Inc.$70
- Novocure Inc.$56
- plus $19 from 1 others
What the payments were for
- Consulting fees$12,02898%
- Food & beverage$1451%
- Education$751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $5,063 |
| Janssen Scientific Affairs, LLC | 6 | $5,025 |
| Janssen Global Services, LLC | 2 | $1,940 |
| Daiichi Sankyo Inc. | 1 | $75 |
| Regeneron Healthcare Solutions, Inc. | 1 | $70 |
| Novocure Inc. | 2 | $56 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$8,278
How this compares
$12,248 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 34 | $479,895 |
| LenvimaLenvatinib Mesylate | 19 | $451,429 |
| EliquisApixaban | 16 | $14,809 |
| Aprepitant | 28 | $4,821 |
| Oxycodone Hcl | 121 | $3,794 |
| Ondansetron Hcl | 39 | $2,064 |
| Fentanyl | 19 | $1,202 |
| Gabapentin | 45 | $1,055 |
| Potassium Chloride | 16 | $923 |
| Dexamethasone | 58 | $743 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $651 |
| Prochlorperazine Maleate | 43 | $650 |
| Levothyroxine Sodium | 82 | $478 |
| Pregabalin | 31 | $473 |
| Sodium Chloride0.9 % Sodium Chloride | 22 | $460 |
Paid to pharmacies, not to this prescriber.
Other adult health in Philadelphia
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$343K
- Abigail SmithPhiladelphia$302K
- Catherine HoldsworthPhiladelphia$64K
- Kevin CarneyPhiladelphia$53K
- Christine ChmielewskiPhiladelphia$52K
- Barbara RogersPhiladelphia$51K
- Joyce RossPhiladelphia$39K
- Veronica RichardsonPhiladelphia$33K
- Tetyana FurmanetsPhiladelphia$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.